Standard-Deviation
Nov
13
2020
Momentum’s Terrible, Horrible, No Good, Very Bad Day!
If Momentum and Growth investors thought they were escaping 2020 unscathed, they learned otherwise on Monday. Pfizer’s promising news about a COVID-19 vaccine was met with universal excitement and investors rearranging portfolios—taking gains in long-term winners and plowing into beaten-down cyclical stocks.